We evaluated Pfizer’s 38-page “5.3.6 Cumulative Analysis of Post-Authorization Adverse Events Reports of PF-07302048 (BNT162b2) received through 28-Feb-2021,” commonly known as “5.3.6,” starting in September of 2022. Patterns emerged across the System Organ Classes (SOCs). These patterns included Pfizer’s apparent concealment of various cases of adverse events, as well as […]
Report 87: In Early 2021, Pfizer Documented Significant Harms and Deaths Following Vaccination with Its mRNA COVID Vaccine. The FDA Did Not Inform the Public.
INTRODUCTION “5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162b2) Received Through 28-Feb-2021,” Pfizer’s post-marketing report, a required U.S. Food and Drug Administration (FDA) compliance document, is one of the ways in which the FDA assessed patients’ risks associated with Pfizer’s COVID-19 vaccine, BNT162b2. The data within the […]
Report 78: Thirty-Two Percent of Pfizer’s Post-Marketing Respiratory Adverse Event Patients Died, Yet Pfizer Found No New Safety Signals.
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a compelling analysis of Respiratory Adverse Events of Special Interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of […]
Report 73: Pfizer Knew by November 2020 That Its mRNA COVID Vaccine Was Neither Safe Nor Effective. Here Is What Pfizer’s Employees and Contractors Knew and When They Knew It.
Introduction Through the review of two documents – Pharmacovigilance Plan for Biologic License Application #125742 Of Covid-19 mRNA vaccine (nucleoside modified) (BNT162b2, PF-07302048) and 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162b2) Received Through 28-Feb-2021 – referred to below as “PV” and “5.3.6,” the contributors to this […]
Report 72: “Other AESIs” Included MERS, Multiple Organ Dysfunction Syndrome (MODS), Herpes Infections, and 96 DEATHS. 15 Patients Were Under Age 12, Including Six Infants.
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a report about Other Adverse Events of Special Interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 […]
Report 71: Musculoskeletal Adverse Events of Special Interest Afflicted 8.5% of Patients in Pfizer’s Post-Marketing Data Set, Including Four Children and One Infant. Women Affected at a Ratio of Almost 4:1 Over Men.
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a review of musculoskeletal adverse events of special interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 […]